Premium
Increased Soluble C 5b‐9 in CSF of Neuromyelitis Optica
Author(s) -
Wang H.,
Wang K.,
Wang C.,
Qiu W.,
Lu Z.,
Hu X.
Publication year - 2014
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/sji.12132
Subject(s) - neuromyelitis optica , multiple sclerosis , cerebrospinal fluid , medicine , pathogenesis , complement system , central nervous system , demyelinating disease , expanded disability status scale , immunology , gastroenterology , antibody
Neuromyelitis optica ( NMO ) and multiple sclerosis ( MS ) are two of the autoimmune inflammatory demyelinating diseases in the central nervous system. Complement is thought to have an important role in pathogenesis of these diseases, especially in NMO . However, the change of terminal complement complex ( TCC , C 5b‐9) in patients with NMO is still unclear. Cerebrospinal fluid ( CSF ) C 3a, C 5a, s C 5b‐9 were measured by enzyme‐linked immunosorbent assay in patients with NMO ( n = 26), MS ( n = 25) and other neurological disease ( OND , n = 19). CSF levels of C 5a in patients with NMO were higher than patients with OND ( P = 0.006). Increased CSF s C 5b‐9 were found in the patients with NMO compared with patients with MS ( P = 0.029) and OND ( P = 0.0001). CSF s C 5b‐9 in patients with MS were also higher than patients with OND ( P = 0.030). Patients with NMO revealed a trend to an increased disease disability with increased CSF s C 5b‐9 during relapse but not in MS ( NMO : P = 0.006, MS: P = 0.097). CSF levels of s C 5b‐9 are increased in patients with NMO and reflect the activation of complement in NMO .